Everything below concerns lyophilisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
=== Decreased lactose content === During the fermentation process, bacteria and yeast break lactose down into glucose and galactose. As a result of the fermentation, lactose levels are decreased by 20–30% with respect to the initial lactose levels present in the milk. One study found that when people with lactose intolerance consumed the same amount of lactose in milk, kefir or yogurt products, the latter two showed significantly reduced symptoms of lactose intolerance during the first 8 hours after consumption. This result suggests that yogurt and kefir might be suitable for people with lactose intolerance. However, the long-term impact of kefir consumption on lactose intolerance has not been studied. It has also been shown that fermented milk products have a slower transit time than milk, which may further improve lactose digestion.
During the Heian period (794 – 1185), the main use of cattle was for bullock carts. Cattle that excelled in this use were called sun-gyū (駿牛, swift bulls) and were regarded as excellent bulls. Owning such an excellent bull became a source of pride for the aristocrats of Japan at that time. The "Pictorial Record of Swift Bulls" (駿牛絵詞) which is believed to have been written around 1279, is said to be the world's oldest specialized book on bulls. In the same book, the names of 52 bulls are listed as swift bulls. At the time, the cattle from Iki Island in present-day Nagasaki Prefecture had the highest reputation as swift bulls, but they were temporarily destroyed by the Mongolian army during the Mongolian invasion, which killed them and used them as food. From the Kamakura period (1185–1333) to the Muromachi period (1336–1573), farming using cattle and horses became popular mainly in western Japan, contributing greatly to the development of agriculture. In a complaint by a farmer in 1423, describing the wrongdoing of a manor administrator, it mentions that the farmer owned cattle and used them for farming.
Premature menopause Gonadal dysgenesis, Turner syndrome, Klinefelter syndrome Castration Swyer syndrome Polyendocrine metabolic ovarian syndrome Certain forms of congenital adrenal hyperplasia Testicular failure Pregnancy – BetaHCG can mimic LH so tests may show elevated LH Note: A medical drug for inhibiting luteinizing hormone secretion is butinazocine.
== Clinical significance == The importance of the MC4R in the regulation of human body weight first became apparent in 1998 with the reports from two groups of single families in whom heterozygous frameshift mutations in MC4R cosegregated with dominantly inherited severe early-onset obesity. In 2009, two very large genome-wide association studies of body mass index (BMI) confirmed the association of common variants about 150 kilobases downstream of the MC4R gene with insulin resistance, obesity, and other anthropometric traits. MC4R may also have clinical utility as a biomarker for predicting individual susceptibility to drug-induced adverse effects causing weight gain and related metabolic abnormalities. Another GWAS performed in 2012 identified twenty SNPs located ~190 Kb downstream of MC4R in association with severe antipsychotic-induced weight gain. This locus overlapped with the region previously identified in the 2009 studies. The rs489693 polymorphism, in particular, sustained a statistically robust signal across three replication cohorts and demonstrated consistent recessive effects. This finding was replicated again by another research group in the following year. In accordance with the above, MC4 receptor agonists have garnered interest as potential treatments for obesity and insulin resistance, while MC4 receptor antagonists have attracted interest as potential treatments for cachexia. The structures of the receptor in complex with the agonist setmelanotide and the antagonist SHU9119 have been determined.
This enzyme, from peppermint converts (+)-pulegone to a mixture of (–)-menthone and (+)-isomenthone using nicotinamide adenine dinucleotide phosphate (NADPH) as its cofactor. It does not act in the opposite direction
Sources: en.wikipedia.org
More than 90% of world industrial production of urea is for use as a nitrogen-release fertilizer. Urea has the highest nitrogen content of all solid nitrogenous fertilizers in common use. Therefore, it has a low transportation cost per unit of nitrogen nutrient. Urea breaks down in the soil to give ammonium ions (NH+4). The ammonium is taken up by the plant through its roots. In some soils, the ammonium is oxidized by bacteria to give nitrate (NO−3), which is also a nitrogen-rich plant nutrient. The loss of nitrogenous compounds to the atmosphere and runoff is wasteful and environmentally damaging so urea is sometimes modified to enhance the efficiency of its agricultural use. Techniques to make controlled-release fertilizers that slow the release of nitrogen include the encapsulation of urea in an inert sealant, and conversion of urea into derivatives such as urea-formaldehyde compounds, which degrade into ammonia at a pace matching plants' nutritional requirements. The most common impurity of synthetic urea is biuret, which impairs plant growth.
=== As an enzyme for catalytic activity === Cytochrome c has also been widely studied as an enzyme with peroxidase-like activity. Cytochrome c was conjugated to charged polymer to test its peroxidase-like activity. Inspired from natural examples of enzyme encapsulation in protein-based cage structures (Example: Carboxysomes, ferritin, and encapsulin), Cytochrome c was encapsulated in a 9 nm small self-assembling DNA binding protein from nutrient starved cells (Dps) protein cage using chimeric self-assembly approach. Authors observed unique catalytic activity behavior upon encapsulating enzyme inside a protein-cage, which was different from enzyme in solution. This was attributed to local microenvironment provided by Dps nanocage's interior cavity which is different than bulk.
Wastewater treatment plants (WWTPs) are designed to remove contaminants from domestic and industrial wastewater before it is released into the environment. However, some WWTPs, particularly older or under-resourced ones are not equipped to effectively remove all CEC, such as advanced pharmaceuticals, personal care product ingredients, and certain types of industrial chemicals. These substances can pass through the treatment process and enter aquatic ecosystems, which creates a challenge for water treatment technology and emphasizes the need for ongoing research and infrastructure improvement to address the removal of CEC from wastewater. Advances like tertiary treatment stages, which incorporate advanced filtration and chemical removal techniques, are being tested to address the presence of CEC in waste, though widespread implementation is yet to be seen due to novelty, cost, and logistical challenges.
== Criticism and decline == In June 2019 a counter-subreddit, r/CantelmoismExposed, was created. Its moderators and other users criticized the medical claims, the targeting of younger Reddit users, the encouragement of practices such as staring at the sun, and what they described as cult-like dynamics. Cantelmo’s responses to critics sometimes included insults. In one AMA he told a skeptical cancer patient to “fuck off.” Cantelmo’s main Reddit account was banned in July 2019 for harassment, including the doxxing of a mental-health professional who had contacted authorities after Cantelmo made suicidal statements. Cantelmo continued posting from alternate accounts. He also directed hostility toward family members and former friends who expressed concern about his mental state and spending. By late 2019 the volume of award-giving had decreased as funds were depleted. Many participants who had been drawn by the awards became less active. Cantelmo’s brother later stated that Cantelmo had spent a large portion of his retirement savings. James Kent, writing in 2022, cited Cantelmo’s case in a discussion of the risks of frequent DMT use, noting reports of psychosis, grandiose delusions, and detachment from reality associated with multiple daily sessions over extended periods.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.